Promoterless gene targeting without nucleases ameliorates haemophilia B in mice

Nature

Volumn 517, Issue 7534, 2015, Pages 360-364

  Barzel, A ^a   Paulk, N K ^a   Shi, Y ^b   Huang, Y ^a   Chu, K ^a   Zhang, F ^a   Valdmanis, P N ^a   Spector, L P ^a   Porteus, M H ^c   Gaensler, K M ^b   Kay, M A ^a  

^a Departments of Bioengineering and Genetics   (United States)

^b Department of Medicine ^*  (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BLOOD CLOTTING FACTOR 9; NUCLEASE; PARVOVIRUS VECTOR; ENDONUCLEASE; SERUM ALBUMIN; STOP CODON;

GENE EXPRESSION; GENOME; PLASMA; PROTEIN; RECOMBINATION; RODENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING TIME; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TARGETING; HEMOPHILIA B; IMMUNOHISTOCHEMISTRY; MOUSE; NEWBORN; NONHUMAN; NORTHERN BLOTTING; PARTIAL HEPATECTOMY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DEPENDOPARVOVIRUS; DISEASE MODEL; GENETICS; HUMAN; LIVER; LIVER CELL; MALE; METABOLISM; PHYSIOLOGY; PROCEDURES; PROMOTER REGION; RIBOSOME; TRANSGENE;

ADENO-ASSOCIATED VIRUS; MUS;

ALLELES; ANIMALS; CODON, TERMINATOR; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENDONUCLEASES; FACTOR IX; FEMALE; GENE TARGETING; HEMOPHILIA B; HEPATOCYTES; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RIBOSOMES; SERUM ALBUMIN; TRANSGENES;

EID: 84923138903     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13864     Document Type: Article

References (35)

1. Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).
2. Hacein-Bey-Abina, S. et al. Insertional oncogenesis in 4 patients after retrovirusmediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142 (2008).
3. Gaj, T., Gersbach, C. A. & Barbas, C. F. III. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
4. Hendel, A. et al. Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. Cell Rep. 7, 293-305 (2014).
5. Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132-141 (2014).
6. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnol. 31, 822-826 (2013).
7. Donsante, A. et al. AAV vector integration sites inmouse hepatocellular carcinoma. Science 317, 477 (2007).
8. Lisowski, L. et al. Ribosomal DNA integrating rAAV-rDNA vectors allow for stable transgene expression. Mol. Ther. 20, 1912-1923 (2012).
9. Miller, D. G. et al. Gene targeting in vivo by adeno-associated virus vectors. Nature Biotechnol. 24, 1022-1026 (2006).
10. Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217-221 (2011).
11. Shi, Y., Falahati, R., Zhang, J., Flebbe-Rehwaldt, L. & Gaensler, K. M. Role of antigen-specific regulatory CD41CD251 T cells in tolerance induction after neonatal IP administration of AAV-hF.IX. Gene Ther. 20, 987-996 (2013).
12. Paulk, N. K., Loza, L. M., Finegold, M. J. & Grompe, M. AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo. Hum. Gene Ther. 23, 658-665 (2012).
13. Garcia-Martinez, R. et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 58, 1836-1846 (2013).
14. Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreedingandretargeting of adeno-associated viruses. J. Virol. 82, 5887-5911 (2008).
15. Lisowski, L. et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506, 382-386 (2014).
16. Li, C. et al.Singleamino acidmodificationofadeno-associatedvirus capsidchanges transduction and humoral immune profiles. J. Virol. 86, 7752-7759 (2012).
17. Dalkara, D. et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl Med. 5, 189ra176 (2013).
18. Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365 (2011).
19. MacLaren, R. E. et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383, 1129-1137 (2014).
20. Paulk, N. K. et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200-1208 (2010).
21. Cavazza, A., Moiani, A. & Mavilio, F. Mechanisms of retroviral integration and mutagenesis. Hum. Gene Ther. 24, 119-131 (2013).
22. Kim, J. H. et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS ONE 6, e18556 (2011).
23. Johnson, L. A. et al.Gene therapy withhumanandmouse T-cell receptorsmediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
24. Nakai, H. et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79, 214-224 (2005).
25. Si-Tayeb, K., Lemaigre, F. P.&Duncan, S. A. Organogenesisand development of the liver. Dev. Cell 18, 175-189 (2010).
26. Nakai, H. et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75, 6969-6976 (2001).
27. Calcedo, R. & Wilson, J. M. Humoral immune response to AAV. Front. Immunol. 4, 341 (2013).
28. Anguela, X. M. et al. ZFN mediated targeting of albumin "safe harbor" results in therapeutic levels of human factor viii in a mouse model of hemophilia A. Blood 122, 720 (2013).
29. Yew, N. S. & Cheng, S. H. Gene therapy for lysosomal storage disorders. Pediatr. Endocrinol. Rev. 11 (suppl. 1), 99-109 (2013).
30. Balazs, A. B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81-84 (2011).
31. Grimm, D., Pandey, K., Nakai, H., Storm, T. A. & Kay, M. A. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J. Virol. 80, 426-439 (2006).
32. Lu, J., Zhang, F. & Kay, M. A. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. Mol. Ther. 21, 954-963 (2013).
33. Mitchell, C. & Willenbring, H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nature Protocols 3, 1167-1170 (2008).
34. Rogers, G. L. & Hoffman, B. E. Optimal immunofluorescent staining for human factor ix and infiltrating T cells following gene therapy for hemophilia B. J. Genet. Syndr. Gene Ther. Suppl. 1, 012 (2012).
35. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).